Pfizer has announced the appointment of Tina Deignan, Ph.D., formerly of Novartis, as its new oncology commercialization chief, succeeding the retiring Suneet Varma. Deignan, who will officially start in the fall, brings extensive experience from her tenure at Novartis and Bristol Myers Squibb. Varma, who has been with Pfizer for 15 years, will remain until early 2025 to ensure a smooth transition. Pfizer’s strategic hire comes amid its aim to market eight blockbuster cancer drugs by 2030, facilitated by its recent $43 billion acquisition of Seagen. The company has indicated that its oncology segment will remain unaffected by ongoing cost-cutting measures and is well-positioned to take on additional products. Notably, Pfizer and Novartis have overlapping interests in oncology, posing future competition challenges for Deignan.
Pharmaceuticals, Healthcare,United States, Switzerland
https://mergersacquisitions.einnews.com/article/723806463/R64-1hCjLrHkmhUY?ref=rss&ecode=Q1vNcweEggLWKz7L